Tag Archives: in-stent restenosis

El éxito de la angioplastia sobre las CTO por reestenosis disminuye la mortalidad cardíaca

Recurrent Revascularization at 10 Years after Percutaneous Treatment of DES In-Stent Restenosis

Recurrent Revascularization at 10 Years after Percutaneous Treatment of DES In-Stent Restenosis

In stent restenosis (ISR) continues to be the main limitation to the percutaneous treatment of coronary artery disease, with 5 to 10% prevalence after new generation DES stenting. Guideline recommendations for this intervention include new DES stenting and the use of drug coated balloons (DCB). Recurrent ISR stenting rate ranges between 10 and 40%, and

TCT 2023 | ALIGN AR trial

TCT 2023 | ISAR-DESIRE 3: 10-Year Results

In-stent restenosis (ISR) remains the primary limitation of percutaneous treatment for coronary artery disease. The strategy to address this limitation involves the use of drug-eluting stents (DES) or drug-coated balloons (DCB), both of which have proven to be effective and safe therapeutic alternatives. Despite current recommendations, treating ISR continues to be a challenge, and clinical

Los balones farmacológicos pasaron la prueba del tiempo en territorio femoropoplíteo

Drug-Eluting Balloons Find Their Niche

According to this large European registry, drug-eluting balloons (DEBs) are competing with drug-eluting stents (DES) to treat in-stent restenosis. Drug-eluting balloons seem to work equally well for the treatment of long-term in-stent restenosis compared with new stent implantation (for the thin-strut DES registry). If DEBs can compete with DES—adding to the advantage of avoiding a

El éxito de la angioplastia sobre las CTO por reestenosis disminuye la mortalidad cardíaca

In-Stent Restenosis Treatment: Meta-Analysis of 10 Randomized Studies

The best strategy to treat in stent restenosis continues to be a dilemma. A new drug eluting stent (DES) seems to be the simplest treatment, even though it adds metal layers that will make it harder and harder to retreat. Drug coated balloons might be a viable alternative seeing as it seems to enable retreatment,

DES de 2.0 mm para vasos muy pequeños: ¿Es viable?

Drug eluting Stents vs. Drug Coated Balloons for In-Stent Restenosis

The rationale behind the decision to not add another layer of metal to the artery sounded attractive and this was what paved the way for drug coated balloons as an alternative strategy to treat in-stent restenosis. “We’ve already got a stent in place, we only have to dilate and leave the drug” is what we

Top